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Abstract
Background—Cryptococcal meningitis (CM) in Africa is associated with up to 70% mortality at
3 months and 500,000 deaths annually. We examined strategies to improve on fluconazole
monotherapy: addition of flucytosine (5-FC); and/or addition of short-course amphotericin B
(AmB).
Methods—In step 1, previously reported, patients were randomized to receive FLU 1200 mg/d
with or without 5-FC 100 mg/kg/day for 14 days. In step 2, 43 patients were similarly randomised,
with addition of AmB 1 mg/kg/d for 7 days to both arms. After 2 weeks, patients received FLU
monotherapy and were followed to 10 weeks. The primary endpoint was rate of clearance of
infection (early fungicidal activity, EFA). Secondary endpoints related to safety and mortality.
Results—40 patients (25% with Glasgow Coma Scale < 15) were analyzed. EFA for the triple
combination arm was greater than for AmB+FLU: −0.50 ± 0.15 log CFU/day vs. −0.38 ± 0.19 log
CFU/day (p = 0.03); and greater than step 1 with FLU+5-FC (−0.28 ± 0.17) or FLU alone (−0.11
± 0.09). Combined analysis across steps revealed that addition of 5-FC and AmB had significant,
independent additive effects on EFA, with trends toward fewer early deaths with addition of 5-FC
(4/41 vs. 11/39, p = 0.05) and fewer deaths overall with addition of AmB (13/39 vs. 20/40, p =
0.1).
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Conclusions—Addition of 5-FC and short course AmB to high-dose FLU significantly enhance
EFA and may be associated with favourable trends in survival. Both these strategies should be
tested in a larger phase III study.
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Background
Cryptococcal meningitis (CM) is a common, often fatal, AIDS-related infection in areas of
high HIV-prevalence. In many areas of Sub-Saharan Africa it has become the leading cause
of adult meningitis (1-3) and is one of the commonest causes of death among people living
with HIV.(4, 5) Despite roll-out of antiretroviral programs, high numbers of patients still
progress to advanced immunocompromise,(6) at which point they are at risk of clinical
cryptococcal infection.
Mortality in patients with CM in Africa has recently been estimated to be 70% at 3 months
(7) and an urgent need exists to develop more effective antifungal regimens in areas of low
resource and high HIV prevalence. Prior dose escalation studies in Uganda demonstrated
increased rates of clearance of infection with a higher dose of FLU (1200 mg/d),(8) but the
rates observed still did not approach those seen with gold standard 2 week induction therapy
with AmB.(9, 10)Identifying better antifungal regimens, feasible in settings with limited
medical resources and staffing, may improve outcomes. Both the combination oral therapy
of FLU plus 5-FC, and a short course therapy of AmB, should be more sustainable induction
treatments in resource limited settings when compared to 2 weeks AmB induction. A
substantial reduction in cryptococcal organism load can be achieved with 1 week of high-
dose AmB,(11) while the major dose-dependent toxicities of AmB usually become clinically
significant only in the second week of therapy.(10) Therefore, limiting AmB duration to one
week might achieve clinical benefit while reducing drug toxicity, monitoring requirements,
duration of intravenous access, and length of hospitalization.
Early fungicidal activity (EFA), or rate of fungal clearance, is an endpoint that correlates
with clinical outcome.(12) Using EFA as our primary endpoint we have studied 2 additional
approaches to improve on the efficacy of high dose FLU: addition of 5-FC and addition of
short-course AmB. In step 1 of this study, patients were randomised to FLU alone at 1200
mg/d or FLU 1200 mg/d plus 5-FC;(13) in step 2, a short course (7 days) of AmB was added
to both of these arms. The results of step 1 have been published.(13) Herein we focus on the
results of step 2 and present a combined analysis of both steps, acknowledging that the
comparison between step 1 to step 2 is not randomised.
Methods
The study was conducted in Lilongwe, Malawi, at Kamuzu Central Hospital (KCH), a
government-run, tertiary referral hospital serving the Central Region of Malawi, which has a
population of 5.5 million people.(14) The adult prevalence of HIV in Malawi is
approximately 12%.(15) The University of North Carolina Project has a research facility
located on the campus of KCH, which provides clinical and laboratory support to the main
hospital. The Lighthouse Trust Clinic, also co-located on the KCH campus, provides free
HIV care and antiretroviral therapy (ART) to approximately 14,000 out-patients.
This study was conducted by the UNC Project in collaboration with St George’s University
of London. Ethical approval was obtained from the Malawi National Health Sciences
Research Committee, the University of North Carolina Review Board, and the Research
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Ethics Committee for St George’s University of London. The trial was registered
(ISRCTN02725351) at http://www.controlled-trials.com.
Participants and procedures
We enrolled ART-naïve, HIV-1 infected adults with a first episode of cryptococcal
meningitis diagnosed by cerebrospinal fluid (CSF) India Ink (later confirmed by culture or
cryptococcal antigen) or CSF cryptococcal antigen. We excluded patients who were
pregnant or breast-feeding, those with alanine aminotransferase > 1200 iu/L, platelets <
50,000 × 103/mL, neutrophils < 500 × 103/mL, or with any contraindication to the study
medications. In step 2 a creatinine > 2.5 mg/dL was also an exclusion criterion. Written
informed consent was obtained from the patient, or from the next of kin if the patient was
incapable of consent. Patients were stratified according to Glasgow Coma Scale (GCS=15,
or GCS<15) and then randomized to intervention groups using a random computer-
generated list.
The treatment groups for step 1 were: (1) 14 days of FLU 1200mg/day (Pfizer Diflucan
Partnership program), (2) 14 days of FLU 1200mg/day plus 14 days of 5-FC 100 mg/kg/day
(rounded down to the nearest gram per day, given over 4 doses per day; Valeant
Pharmaceuticals). In step 2 patients were randomised to either (1) 14 days of FLU 1200 mg/
day plus 7 days of AmB 1 mg/kg/day (Fungizone, Bristol-Meyers Squibb) or (2) 14 days of
FLU 1200mg/day plus 14 days of 5-FC 100 mg/kg/day plus 7 days of AmB (1 mg/kg/day).
While receiving AmB, all patients received an extra 1 L normal saline with 20 mmol KCl
per day intravenously and extra potassium supplementation as required. AmB was held if
creatinine was greater than 2.5 mg/dL, and restarted if the creatinine dropped to below 2.5
mg/dL.
After 2 weeks all patients were given FLU 800 mg/d until ART was started at 4 weeks, then
400 mg/d until week 10, and 200 mg/d thereafter. FLU and 5-FC doses were adjusted for
renal function. 5-FC was reduced by 50% for grade III neutropenia or thrombocytopenia and
discontinued for grade IV neutropenia or thrombocytopenia. After the first 2 weeks FLU
doses were increased 50% for patients on concomitant rifampicin.
After 4 weeks of antifungal therapy, patients attended the Lighthouse Clinic for initiation of
antiretrovirals (stavudine, lamivudine, and nevirapine) according to Malawi national
guidelines.
Evaluation and outcomes
Lumbar punctures were performed on days 1, 3, 7, and 14 to obtain CSF for quantitative
culture and to document CSF opening pressure. Additional therapeutic LPs, with additional
quantitative culture, were done on patients with previously demonstrated or clinically
suspected raised CSF pressure (>30 cm H2O) in accordance with guidelines.
For quantitative cultures, CSF was plated in serial 10-fold dilution, as previously described.
(16) The dilution with the least colonies, but at least 30 colony-forming units (CFU) per
plate, was used to calculate CFU per millilitre of CSF. Laboratory personnel calculating
quantitative cryptococcal culture results were masked to the treatment group. The decrease
in log CFU/ml CSF/d was calculated using the slope of the linear regression of log CFU
counts against time for each patient.(16) All data points were analyzed except sterile
cultures in the second week if these values lessened the slope, because sterility would have
been achieved before that day’s lumbar puncture and this value would therefore
underestimate the true slope.
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Laboratory tests were processed in the University of North Carolina Project laboratory
(which, with its multiple network studies, undergoes regular quality assurance through
international regulatory bodies). Testing included blood count with differential, aspartate
aminotransferase, alanine aminotransferase, potassium, and creatinine at baseline and then
three times per week in the first 2 weeks. CD4+ cells and HIV load were determined at
baseline. Aspartate aminotransferase and alanine aminotransferase measurements were
performed again at weeks 4, 6, and 10 after study enrolment. Clinical and laboratory adverse
events were graded using the toxicity table from the Division of Acquired
Immunodeficiency Syndrome, National Institute of Allergy and Infectious Diseases,
National Institutes of Health.(17) Percentage changes in laboratory values were calculated
using the following formula: (final value-baseline value/ baseline value) × 100.
The primary outcome measure was the mean rate of decrease in CSF cryptococcal counts or
early fungicidal activity (EFA) for each treatment arm. Secondary outcome measures were
serious adverse events, laboratory toxicities, and mortality at 2 and 10 weeks.
Statistical analysis
We compared baseline characteristics of the treatment groups using Fisher exact or chi-
squared tests for categorical variables and the Mann-Whitney U test or Student’s t-test, as
appropriate, for continuous variables. Linear regression was used to compare early
fungicidal activity by treatment group, adjusting where indicated for other variables, giving
summary differences with 95% confidence intervals (CIs) and significance levels. Mortality
was examined by Fishers exact (with cells of frequency ≤5) and chi squared tests and Cox
regression.
It was initially planned to include 40 patients per arm in step 1, giving >90% power to detect
an increase in early fungicidal activity with addition of 5-FC to high dose fluconazole.(13)
However, at the pre-planned analysis after 40 patients enrolled, the Data Monitoring
Committee (DMC) recommended termination as there was already a statistically significant
difference in EFA, the study’s primary outcome, favouring the combination regimen.
Therefore, the study was modified and completed as step 2, with addition of short course
AmB to both arms, yielding two closely related clinical trials. It was assumed that AmB
would lead to an increase in EFA at least as great as with 5-FC, and that there would be no
significant interaction between AmB and 5-FC and therefore power to detect independent
effects of addition of 5-FC and AmB would be maintained.
Results
Forty-three patients were enrolled in step 2 between May 2009 and March 2010 (Figure 1).
Three patients were withdrawn due to initial false-positive India Ink tests that could not be
later confirmed by culture or CSF cryptococcal antigen. Baseline characteristics were
similar between the arms (Table 1): there were no significant differences between the arms
treated with and without 5-FC in step 2, or when combining step 1 and step 2. When
considering patients enrolled in step 2 compared to step 1, there were no significant
differences, apart from both CD4+ cell count and HIV viral load being lower in step 1
compared to step 2. One patient in the triple combination arm, who relocated to her home
district, was lost to follow up at 4 weeks.
Early fungicidal activity
In step 2, the rate of clearance of infection was more rapid in the triple combination arm
compared with AmB plus FLU: −0.50 +/− 0.15 log CFU/ml/d vs. −0.38 +/− 0.19 CFU/ml/d,
p=0.03) (Figure 2). Fifteen patients in the triple combination arm had sterile CSF at 2 weeks,
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compared to 8 in the AmB plus FLU arm (p = 0.05, fishers exact). In step 2, none of the
other variables examined affected rate of clearance of infection (baseline CFU count, altered
mental status at presentation, CSF opening pressure, tuberculosis treatment, gender, age,
weight, CD4 cell count, viral load).
We next analysed data from steps 1 and 2 together, in order to examine the separate and
combined effects of adding 5-FC and/or short course AmB to high dose fluconazole. In
univariate analyses, 5-FC and short course AmB were each associated with a very
significant increase in the rate of clearance of infection: For 5-FC, the difference was 0.14
log CFU/day (95%CI 0.04-0.23; p = 0.004); for short course AmB the difference was 0.24
log CFU/day (95%CI 0.16-0.32; p < 0.001). In multivariate analysis including both 5-FC
and short course AmB, these estimates of effect were hardly altered suggesting independent
additive effects of the two agents: For 5-FC, the difference was 0.15 log CFU/day (95%CI
0.08-0.22; p <0.001); for short course AmB the difference was 0.25 log CFU/day (95%CI
0.17-0.32; p < 0.001). In the combined data set, only CD4+ cell count was also associated
with rate of clearance of infection (the difference for each increment in CD4+ cell count
quartile 0.05 log CFU/day, 95%CI 0.01-0.09; p = 0.02). Adjusting for CD4 cell count made
no difference to the estimates of the independent effects of AmB and 5-FC.
Mortality
The study was not powered for mortality differences, and there were no statistically
significant differences in survival at 2 and 10 weeks between the arms. However, combining
steps 1 and 2, consistent with the EFA results, there were fewer early deaths with addition of
5-FC (4/41 vs. 11/39, p = 0.05, and 15/40 vs. 18/39, p = 0.4, at 2 and 10 weeks respectively;
hazard ratio (HR) at 2 weeks 0.33 95%CI 0.10-1.03, p = 0.05) and fewer total deaths in step
2, with addition of short course AmB, compared with step 1 (6/40 vs. 9/40, p = 0.4, and
13/39 vs. 20/40, p = 0.1, at 2 and 10 weeks respectively; HR at 10 weeks 0.58 95%CI
0.29-1.17, p = 0.1), although these differences did not reach statistical significance. In step
2, there were fewer presumed cryptococcal meningitis-related deaths in the triple
combination arm compared to the AmB/fluconazole arm (1 vs. 6, p = 0.09). Combining
steps 1 and 2, there were also fewer presumed cryptococcal meningitis-related deaths with
vs. without 5-FC (5 vs. 13, p = 0.03). Kaplan-Meier survival curves for step 1 vs. step 2
(effect of short course AmB) and for addition of 5-FC (both steps) are shown in figure 3.
Safety
Safety for step 1 has previously been reported.(13) Safety for step 2 is discussed here.
Laboratory adverse events in the first 2 weeks are shown in table 2. There were 2 instances
of grade IV neutropenia in patients on 5-FC. One of these occurred on Day 14, so the 14
days of 5-FC therapy had already been given. This patient had a grade II neutropenia at
enrolment (837/mm3), and had recovered to grade I neutropenia (1120/mm3) by day 37. The
other occurred on Day 13, so doses for day 14 were held. Counts for this patient recovered
to grade II neutropenia (750/mm3 – 999/mm3) by the next blood draw. In an additional 5
patients with grade III neutropenia, the 5-FC dose was reduced, as per protocol. There was
no increase in infection-related adverse events among patients receiving 5-FC compared to
those receiving AmB plus fluconazole alone (9 vs. 10 events, with and without 5-FC).
As expected with AmB, there were more instances of anemia and renal impairment in step 2
compared to step 1,(13) but few grade IV events, and only one patient missed more than one
of the planned 7 doses of AmB (in this instance due to raised creatinine). In step 1 the mean
week 1 percentage fall in hemoglobin was 7% compared to 16% in step 2 (p < 0.001).
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In step 1 there was a negligible percent rise in creatinine after 1 and 2 weeks, 1% and 2%,
respectively. By comparison, in step 2, when AmB was used, there were significantly
greater percentage increases in creatinine, 58% after 1 week and 25% after 2 weeks (both p
< 0.05). There was only one instance of grade IV hypokalemia, which occurred in a patient
in the dual therapy arm on day 11 (4 days after completing AmB) and was partly attributed
to persistent vomiting. Levels responded to fluid and potassium replacement.
FLU 1200 mg/d was well tolerated. There were 2 instances of grade III hepatic transaminase
elevation during the first 2 weeks in step 2 (with none in step 1), both of which occurred at
times of concurrent bacterial infection and resolved without interruption of FLU. One
additional patient developed grade IV hepatic transaminitis on day 18 (FLU dose 800 mg/d)
at the time of concurrent pneumonia. Fluconazole was held temporarily, and upon restarting
there was no further liver test abnormality leading us to consider this unlikely related to
FLU. No significant rises in transaminases were seen when ART with nevirapine was started
at 4 weeks.
Two patients had a syndrome compatible with cryptococcal immune reconstitution
inflammatory syndrome, both in the triple therapy arm. Both of these patients improved with
therapeutic LPs and survived to the end of follow-up.
Discussion
Addition of either 5-FC or short course AmB to high dose FLU treatment for CM led to
statistically significant and substantial increases in the rate of clearance of infection from the
CSF. The magnitudes of the increases are such that would be expected to translate into
clinical benefit, (12) a conclusion supported by favourable trends, although not statistically
significant, in 2 and 10 week survival,. Furthermore, in the longer term in resource limited
settings, both of these interventions could be more sustainable than 2-week AmB induction,
given that the rapid and reliable laboratory monitoring and extra costs required to give AmB
safely for 2 weeks are often not available.
Addition of short course AmB to FLU had a larger impact on rate of clearance of infection
over the first 2 weeks than did addition of 5-FC, with the caveat that this comparison,
between steps 1 and 2, was not based on randomized groups, but sequential groups in the
same study setting. The rates of clearance seen with 7 days of AmB were similar to those
previously measured with full 2 weeks courses (10, 16, 18). As previously observed in Cape
Town and in Uganda, (11, 19) there was no detectable reduction in clearance rate in the
second week, after AmB had been discontinued, which is consistent with fact that AmB has
a relatively long half-life, particularly in the brain and meningeal tissues. Renal impairment
and anemia appeared less severe than in prior studies with 2 week courses of AmB at 1 mg/
kg/d, (10) and with regular potassium supplementation severe hypokalemia was rare. AmB
side effects were more frequent than in an observational cohort from Uganda where a
shorter course of 5 days of AmB combined with fluconazole 1200mg/day for 2 weeks was
also associated with a marked increase in fungicidal activity (to −0.30 ± 0.11 log CFU/day)
compared with historical controls from that site treated with fluconazole monotherapy (19).
While some AmB induction is likely better than none, the maximum duration that can
administered safely in the absence of reliable laboratory monitoring may be less than one
week. AmB had not previously been used as part of routine induction therapy in Malawi,
and thus step 2 provided invaluable experience with its use in one of the country’s principal
referral centers. At Kamuzu Central Hospital, with monitoring support through the UNC
Project, one week AmB plus FLU was adopted as the standard treatment for CM.
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There were 2 instances of grade IV neutropenia in patients on 5-FC in step 2. Overall, in
studies by our group, including both steps of this study, 5-FC at this dosage and duration has
been associated with grade IV neutropenia in 8/183 (4.4%) of patients (13, 16, 18, 20, 21).
In Thailand, the bioavailability of oral 5-FC in patients with CM was only around 50%, and
the levels of 5-FC were well below those usually associated with toxicity. 5-fluorouracil was
infrequently detected in serum.(20) However, given the probable importance of the gut flora
in conversion of 5-FC to 5-fluorouracil, the pharmacokinetics of 5-FC and 5-fluorouaracil
may be different across geographically and ethnically diverse populations. Planned analyses
of 5-FC and 5-fluorouracil levels in serum and CSF from our patients will help determine
whether the pharmacokinetics of 5-FC in HIV patients are different in Africa compared to
Asia and will help determine whether the neutropenia observed in this study was causally
related to 5-FC.
Finally, although this was not a true factorial study design, the combined analysis of steps 1
and 2 suggests that, in the context of high dose FLU, 5-FC and AmB have largely
independent, additive effects on the rate of clearance of infection. Unlike a 2004 study in
Thailand in which FLU was dosed at 400 mg/d,(16) the triple combination of these agents at
our protocol doses gave the most rapid clearance of all the regimens. Data since 2004 have
convincingly shown that higher induction doses (1200 mg/d) of FLU are more effective and
appear safe.(8, 13, 22, 23) The nature of the interaction between agents in combination may
be different at different dosages of the individual components. Our results are consistent
with the mouse model data in which optimal responses were seen when high doses of AmB
and FLU were combined with a moderate dose of 5-FC.(24)
While both of our experimental strategies improve EFA compared to FLU alone, the
implementation of the oral only combination of FLU/5-FC may have broader application
across rural health centers. Although previously registered and marketed in South Africa, 5-
FC is not generally available in Sub Saharan Africa. However, it is a simple molecule and
could be produced at low cost by generic manufacturers. The addition of Amphotericin
based therapy, with reduced duration, may also be feasible at rural centers based on the
safety profile we observed, though we acknowledge our research setting is well resourced
compared to rural health centers.
In summary, the results from this study lend strong support to a planned phase III trial in
resource limited centres comparing both the optimal oral combination of high dose FLU plus
5-FC and short course AmB with standard 2 week induction therapy with AmB. In addition,
further studies are warranted with triple therapy, and efforts should continue to increase the
availability of 5-FC in Africa and Asia, where the burden of cryptococcal disease remains
unacceptably high.
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Fluco = fluconazole; AmB = amphotericin B; 5-FC = flucytosine
PHASE 1 – before amphotericin amendment
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Decrease in Cryptococcus neoformans CFU over time, by treatment group. Dotted lines
represent a threshold of 1 × 104 CFU/mL to aid visual comparison. Each line represents
results from a single patient. In combined analysis, the mean rate of decrease of log CFU, or
early fungicidal activity (EFA), was significantly more rapid for patients receiving vs. not
receiving 5-FC, and for patients receiving vs. not receiving short course AmB (p < 0.001,
both comparisons).
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Survival curves, A. Step 1 vs. step 2 (effect of short course AmB). B. With and without 5FC
(steps combined). There were trends towards fewer deaths at 10 weeks with AmB (HR 0.58
95%CI 0.29-1.17, p = 0.1), and fewer early deaths with 5FC (HR 0.33 95%CI 0.10-1.03, p =
0.05)
Kaplan Meier by study arm
Effect of AmB (step 1 compared to step 2)
Effect of flucytosine on survival – across all steps
Effect of flucytosine in step 1 only
Effect of flucytosine in step 2 only
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Table 2
Laboratory adverse events in the first 2 weeks.
Adverse event Fluconazole + AmB 5FC + Fluconazole + AmB
Grade III Grade IV Grade III Grade IV
Thrombocytopenia 1
Neutropenia 4 3 2
Anemia 5 2 4
Hypokalemia 2 1 2
Hyperkalemia 1
Hyponatremia 1 1
Renal Impairment 5 4
Transaminitis 1 1
Cut-offs used to define grade III and grade IV laboratory abnormalities respectively were as follows: Thrombocytopenia: Platelet count: 25,000–
49,999 platelets/mm3 and < 25,000 platelets/mm3; Neutropenia: Absolute neutrophil count, 500–749 cells/mm3 and < 500 cells/mm3; Anemia:
Hemoglobin concentration: 6.5–7.4 g/dL and < 6.5 g/dL; Transaminitis: Alanine aminotransferase level, 175–350 IU/L and >350 IU/L; Aspartate
aminotransferase level, 190–380 IU/L and > 380 IU/L; Hyponatremia: Sodium level: 121–124 mmol/L and < 120mmol/L; Renal impairment:
Creatinine level: 2.2–4.1 mg/dL and > 4.1 mg/dL for men and 2.3-4.4 mg/dL and > 4.4 mg/dL for women.
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